CD8A and cancer: The isolation of splicetope-specific CD8+ T cells from cancer patients and the finding that splicetope-specific CD8+ T cells derived from tumor-infiltrating lymphocytes (TILs) inhibited the engraftment of human acute myeloid leukemia cells in SCID mice indicated the potential immune relevance of such tumor antigen-derived splicetopes (Robbins et al., 1994).